Allergic rhinitis is a very common condition (affecting 1 in 5 people in Europe) and a costly one for society (direct and indirect costs). Symptoms vary depending on the time of year, and treatments are primarily symptomatic, with follow-up in ENT consultations. Scientific societies (EAACI, FDA, EMA) recommend using a universal tool (severity score) (the CSMS score, SCST in French) to monitor severity and follow-up, and to obtain consistent data that can be extrapolated to other scientific data (meta-analyses).
Therefore, investigators in the ENT department use this SCST score (as well as others such as the SNOT 22 score) to assess the severity of allergic rhinitis in our patients and its progression.
Tbe investigators wish to confirm the acceptability of this tool for patients, and the statistical value of its properties.
Adult (≥18 years)
Follow-up at the ENT department of Hautepierre University Hospital for allergic rhinitis
Asymptomatic individuals not requiring follow-up consultations.
Adult (≥18 years) having follow-up at the ENT department of Hautepierre University Hospital for allergic rhinitis
Case-only
Retrospective
Not listed
Self-Assessment Clinical Symptom Score (SCST)
1. Rating Scale Each symptom is rated by the patient according to its intensity: * 0: absent * 1: mild * 2: moderate * 3: severe 2. Calculating the Score * Add the scores for each symptom. * The total SCST score reflects the overall severity of the symptoms: * Low score → mild symptoms * High score → severe symptoms 3. Interpretation * Before treatment: establish a baseline. * After treatment: compare the scores to assess effectiveness. * A decrease in the score indicates clinical improvement.
Click on the lead sponsor to view all of their trials.
